Your browser is no longer supported. Please, upgrade your browser.
Settings
STML Stemline Therapeutics, Inc. daily Stock Chart
STML [NASD]
Stemline Therapeutics, Inc.
Index- P/E- EPS (ttm)-3.04 Insider Own8.30% Shs Outstand43.35M Perf Week12.82%
Market Cap656.32M Forward P/E- EPS next Y-0.52 Insider Trans-5.86% Shs Float39.00M Perf Month4.05%
Income-94.00M PEG- EPS next Q-0.58 Inst Own78.50% Short Float13.74% Perf Quarter13.32%
Sales5.50M P/S119.33 EPS this Y-1.80% Inst Trans66.09% Short Ratio10.50 Perf Half Y46.14%
Book/sh2.90 P/B5.22 EPS next Y78.70% ROA-98.90% Target Price29.43 Perf Year-14.94%
Cash/sh2.87 P/C5.27 EPS next 5Y- ROE-127.10% 52W Range7.82 - 18.02 Perf YTD59.37%
Dividend- P/FCF- EPS past 5Y-5.00% ROI-204.50% 52W High-13.29% Beta1.28
Dividend %- Quick Ratio5.00 Sales past 5Y47.80% Gross Margin98.50% 52W Low99.87% ATR0.81
Employees91 Current Ratio5.10 Sales Q/Q- Oper. Margin- RSI (14)64.16 Volatility5.49% 5.39%
OptionableYes Debt/Eq0.00 EPS Q/Q-6.40% Profit Margin- Rel Volume0.65 Prev Close15.14
ShortableYes LT Debt/Eq0.00 EarningsMay 10 BMO Payout- Avg Volume510.59K Price15.63
Recom1.90 SMA2010.40% SMA508.41% SMA20018.16% Volume330,392 Change3.24%
May-13-19Downgrade Wedbush Outperform → Neutral $18
Dec-11-18Initiated JP Morgan Overweight $17
Nov-26-18Initiated Piper Jaffray Overweight $20
Jun-12-18Initiated ROTH Capital Buy $30
Nov-01-17Reiterated H.C. Wainwright Buy $34 → $38
Feb-06-17Reiterated Wedbush Outperform $19 → $11
Mar-15-16Reiterated Wedbush Outperform $19 → $15
Apr-27-15Initiated H.C. Wainwright Buy $38
Apr-22-15Resumed Jefferies Buy
Jan-26-15Reiterated ROTH Capital Buy $62 → $50
Oct-30-13Reiterated Aegis Capital Buy $40 → $70
Jun-19-19 10:39AM  Hedge Funds Have Never Been This Bullish On Stemline Therapeutics Inc (STML) Insider Monkey
Jun-17-19 07:30AM  Stemline Therapeutics Announces Presentation of ELZONRIS (tagraxofusp) Preclinical Data in Systemic Sclerosis, an Autoimmune Disorder, at EULAR Congress GlobeNewswire +5.79%
Jun-13-19 07:30AM  Stemline Therapeutics Announces Three ELZONRIS (tagraxofusp) Clinical Presentations at EHA Congress June 13-15 GlobeNewswire +5.79%
Jun-03-19 01:40PM  When Will Stemline Therapeutics, Inc. (NASDAQ:STML) Turn A Profit? Simply Wall St.
07:30AM  Stemline Therapeutics Announces ASCO Presentation of ELZONRIS Phase 2 Clinical Data in CMML and MF; Provides Next Steps for CMML Program GlobeNewswire
May-26-19 11:25PM  Edited Transcript of STML earnings conference call or presentation 10-May-19 12:00pm GMT Thomson Reuters StreetEvents
May-20-19 07:00AM  Stemline Therapeutics Announces ELZONRIS Clinical Data Selected for Presentation at Upcoming EHA Annual Congress GlobeNewswire
May-16-19 07:00AM  Stemline Therapeutics Announces ELZONRIS Clinical Data Selected for Presentation at the Upcoming ASCO Annual Meeting GlobeNewswire
May-13-19 10:02AM  Wedbush: Trajectory For Stemline Therapeutics' Blood Cancer Drug Priced Into Stock Benzinga -10.34%
May-10-19 06:46PM  Stemline Therapeutics, Inc. (STML) Q1 2019 Earnings Call Transcript Motley Fool
07:45AM  Stemline Therapeutics (STML) Reports Q1 Loss, Tops Revenue Estimates Zacks
06:40AM  Stemline Therapeutics: 1Q Earnings Snapshot Associated Press
06:30AM  Stemline Therapeutics Reports First Quarter 2019 Financial Results GlobeNewswire
May-08-19 07:00AM  Stemline Therapeutics to Host Conference Call on First Quarter 2019 Financial Results on May 10, 2019 GlobeNewswire
Apr-25-19 07:00AM  Stemline Therapeutics Announces New England Journal of Medicine Publication of ELZONRIS (tagraxofusp) Pivotal Study Results GlobeNewswire
Apr-23-19 12:20PM  Announcing: Stemline Therapeutics (NASDAQ:STML) Stock Increased An Energizing 150% In The Last Three Years Simply Wall St. +5.26%
Apr-01-19 07:50AM  Research Report Identifies Oracle, Realty Income, Stemline Therapeutics, WhiteHorse Finance, EverQuote, and Sanderson Farms with Renewed Outlook Fundamental Analysis, Calculating Forward Movement GlobeNewswire
Mar-18-19 07:00AM  Stemline Therapeutics to Participate in Panel on Myeloid Tumors at the 31st Annual ROTH Conference GlobeNewswire -5.29%
Mar-15-19 04:18PM  Stemline Therapeutics: 4Q Earnings Snapshot Associated Press
04:01PM  Stemline Therapeutics Reports Fourth Quarter 2018 Financial Results GlobeNewswire
Mar-11-19 07:00AM  Stemline In-Licenses Worldwide Rights to Novel Selective RET Inhibitor (SL-1001); Expands Oncology Pipeline GlobeNewswire
Mar-06-19 07:30AM  Stemline Therapeutics to Present at the Cowen and Company 39th Annual Health Care Conference GlobeNewswire
Feb-19-19 11:30AM  Is Stemline Therapeutics, Inc. (NASDAQ:STML) Excessively Paying Its CEO? Simply Wall St.
Jan-30-19 07:30AM  Stemline Therapeutics Announces Validation of Marketing Authorization Application (MAA) by the European Medicines Agency (EMA) GlobeNewswire
Jan-24-19 07:55AM  Consolidated Research: 2019 Summary Expectations for Marriott International, Calavo Growers, Kinsale Capital Group, Fluidigm, Goldman Sachs BDC, and Stemline Therapeutics Fundamental Analysis, Key Performance Indications GlobeNewswire
Jan-21-19 10:20AM  Read This Before Buying Stemline Therapeutics, Inc. (NASDAQ:STML) Shares Simply Wall St.
Jan-18-19 11:21AM  Stemline Therapeutics Closes $92 Million Public Offering of Common Stock GlobeNewswire
Jan-16-19 09:01AM  Stemline Therapeutics (STML) in Focus: Stock Moves 9.5% Higher Zacks
Jan-15-19 10:04PM  Stemline Therapeutics Announces Upsizing and Pricing of $80 Million Public Offering of Common Stock GlobeNewswire +9.47%
Jan-14-19 04:35PM  Stemline Therapeutics Announces Proposed Public Offering of Common Stock GlobeNewswire -8.19%
Jan-07-19 09:50AM  Stemline Therapeutics Announces Submission of European Marketing Authorization Application (MAA) for ELZONRIS GlobeNewswire
Jan-02-19 07:30AM  Stemline Therapeutics to Present at the 37th Annual J.P. Morgan Healthcare Conference GlobeNewswire
Dec-26-18 12:31PM  Stemline's Elzonris Launch On Schedule, HC Wainwright Says In Bullish Initiation Benzinga +12.55%
09:34AM  Biotech Stock Roundup: ALXN, ACOR Drugs' Get FDA Nod, AGEN up on GILD Deal Zacks
Dec-22-18 08:25AM  Why We Think Stemline Therapeutics, Inc. (NASDAQ:STML) Could Be Worth Looking At Simply Wall St.
Dec-21-18 02:55PM  FDA Approves ELZONRIS (tagraxofusp), the First Treatment for Blastic Plasmacytoid Dendritic Cell Neoplasm and First CD123-Targeted Therapy PR Newswire -5.18%
01:49PM  U.S. FDA approves Stemline Therapeutics' rare blood disease treatment Reuters
12:25PM  These 4 Biotech Stocks Are Raising Eyebrows ACCESSWIRE
Dec-07-18 01:29PM  Stemline Therapeutics (STML): Elzonris Approval Dawning on the Horizon, Says Analyst SmarterAnalyst
07:00AM  3 Biotech Stocks That Could Explode Higher in 2019 SmarterAnalyst
Dec-06-18 07:00AM  Stemline Therapeutics Recaps Key Clinical Data Presentations from the American Society of Hematology (ASH) Annual Meeting GlobeNewswire
Nov-30-18 07:00AM  Stemline Therapeutics Highlights Four ELZONRIS Presentations, Including an Oral Presentation, at the Upcoming ASH Meeting GlobeNewswire +8.60%
Nov-27-18 08:30AM  Report: Developing Opportunities within Koppers, Flowers Foods, Stemline Therapeutics, Aqua Metals, athenahealth, and Bojangles' Future Expectations, Projections Moving into 2018 GlobeNewswire -11.98%
Nov-21-18 02:59PM  What Kind Of Investor Owns Most Of Stemline Therapeutics Inc (NASDAQ:STML)? Simply Wall St. +11.40%
Nov-20-18 07:00AM  Stemline Therapeutics Announces that European Medicines Agency (EMA) Grants Accelerated Assessment for planned ELZONRIS Marketing Authorization Application (MAA) GlobeNewswire
Nov-16-18 07:30AM  Stemline Therapeutics Announces Oral Presentation of SL-701 Phase 2 Data in Second-Line Glioblastoma at the 23rd Annual Meeting of the Society of Neuro-Oncology (SNO) GlobeNewswire
Nov-08-18 05:17PM  Stemline Therapeutics: 3Q Earnings Snapshot Associated Press
04:01PM  Stemline Therapeutics Reports Third Quarter 2018 Financial Results GlobeNewswire
Nov-02-18 07:30AM  Stemline Therapeutics Announces Four ELZONRIS Presentations, Including an Oral Presentation, at Upcoming ASH Meeting GlobeNewswire
Oct-16-18 07:30AM  Stemline Therapeutics Announces SL-701 and SL-801 Clinical Data to be Featured, Including an Oral Presentation, at Upcoming ESMO 2018 Congress GlobeNewswire +6.21%
Oct-11-18 08:20AM  Consolidated Research: 2018 Summary Expectations for Casella Waste, ServiceNow, MKS Instruments, FirstEnergy, Stemline Therapeutics, and CMS Energy Fundamental Analysis, Key Performance Indications GlobeNewswire
Oct-09-18 05:50PM  Newman Ferrara LLP Announces Corporate Governance Investigation of Stemline Therapeutics Inc. - STML Business Wire
Sep-28-18 07:00AM  Stemline Therapeutics to Present at Upcoming Investor Conferences GlobeNewswire
Sep-18-18 02:37PM  When Will Stemline Therapeutics Inc (NASDAQ:STML) Turn A Profit? Simply Wall St.
Sep-05-18 07:00AM  Stemline Therapeutics to Present at the H.C. Wainwright 20th Annual Global Investment Conference GlobeNewswire
Aug-14-18 07:30AM  Stemline Therapeutics to Present at the 2018 Wedbush PacGrow Healthcare Conference GlobeNewswire
Aug-13-18 09:25AM  Benzinga Pro's 5 Stocks To Watch Today Benzinga
06:30AM  Stemline Therapeutics Announces that FDA Accepts ELZONRIS Biologics License Application (BLA) and Grants Priority Review GlobeNewswire
Aug-09-18 08:18AM  Stemline Therapeutics: 2Q Earnings Snapshot Associated Press +5.63%
08:00AM  Stemline Therapeutics Reports Second Quarter 2018 Financial Results GlobeNewswire
Aug-06-18 07:55AM  Report: Developing Opportunities within Stemline Therapeutics, Silgan, CVR Energy, MINDBODY, FireEye, and Quality Future Expectations, Projections Moving into 2018 GlobeNewswire
Jun-25-18 07:00AM  Stemline Therapeutics Announces Completion of Rolling BLA Submission for ELZONRIS (tagraxofusp; SL-401) for the Treatment of BPDCN GlobeNewswire
Jun-19-18 10:00AM  Biotechnology Firm PPCB, Shows Great Potential ACCESSWIRE
Jun-18-18 07:00AM  Stemline Therapeutics Announces Positive Clinical Data from ELZONRISTM (tagraxofusp; SL-401) Trials in BPDCN, CMML and MF Delivered at the EHA Congress GlobeNewswire
Jun-15-18 08:15AM  Stemline Therapeutics Announces Presentation of ELZONRIS (tagraxofusp; SL-401) Preclinical Data in Systemic Sclerosis, an Autoimmune Disorder, at EULAR Congress GlobeNewswire
Jun-14-18 07:00AM  Stemline Therapeutics Announces Three ELZONRIS (tagraxofusp; SL-401) Clinical Presentations, Including an Oral Presentation, at the EHA Congress GlobeNewswire
Jun-05-18 07:00AM  Stemline Therapeutics Announces Positive Data Presentations on SL-701 and SL-801 at ASCO GlobeNewswire
May-22-18 07:20AM  Wired News - Stemline Therapeutics' SL-401 BPDCN Program Selected for Clinical Presentations at Upcoming EHA Congress ACCESSWIRE
May-18-18 07:00AM  Stemline Therapeutics Announces Three SL-401 Clinical Presentations, Including an Oral Presentation, at the Upcoming EHA Congress GlobeNewswire
May-17-18 07:00AM  Stemline Therapeutics Announces Presentation of SL-801 and SL-701 Clinical Data at the Upcoming ASCO Annual Meeting GlobeNewswire
May-09-18 04:26PM  Stemline Therapeutics: 1Q Earnings Snapshot Associated Press
04:00PM  Stemline Therapeutics Reports First Quarter 2018 Financial Results GlobeNewswire
May-02-18 06:04PM  SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces an Investigation Concerning Possible Breaches of Fiduciary Duty by Certain Officers and Directors of Stemline Therapeutics, Inc. Business Wire
May-01-18 01:43PM  SHAREHOLDER ALERT: Purcell Julie & Lefkowitz LLP Is Investigating Stemline Therapeutics, Inc. for Potential Breaches Of Fiduciary Duty By Its Board of Directors PR Newswire
Apr-30-18 08:25AM  Report: Exploring Fundamental Drivers Behind Agilysys, Editas Medicine, The ExOne, Central Garden & Pet, Quality, and Stemline Therapeutics New Horizons, Emerging Trends, and Upcoming Developments GlobeNewswire
Apr-26-18 07:00AM  Stemline Therapeutics Announces Clinical Presentations of SL-801 and SL-701 at the Upcoming ASCO Annual Meeting GlobeNewswire
Apr-16-18 07:00AM  Stemline Therapeutics Expands Board of Directors; Further Enhances Commercial Expertise with Appointment of Darren Cline GlobeNewswire
Apr-09-18 07:10AM  Wired News Stemline Therapeutics Initiates Rolling BLA Submission for SL-401 ACCESSWIRE +7.28%
Apr-05-18 07:00AM  Stemline Therapeutics Announces Start of Rolling BLA Submission for SL-401 GlobeNewswire
Mar-19-18 07:50AM  Report: Exploring Fundamental Drivers Behind Fluidigm, Acuity Brands, TTEC, Actuant, Equity Lifestyle Properties, and Stemline Therapeutics New Horizons, Emerging Trends, and Upcoming Developments GlobeNewswire
07:30AM  Stemline Therapeutics to Present at the Oppenheimer 28th Annual Healthcare Conference GlobeNewswire
Mar-16-18 08:05AM  Stemline Therapeutics reports 4Q loss Associated Press -6.33%
07:30AM  Stemline Therapeutics Reports Fourth Quarter 2017 Financial Results GlobeNewswire
Mar-14-18 07:34AM  Breakeven On The Horizon For Stemline Therapeutics Inc (NASDAQ:STML) Simply Wall St.
Mar-08-18 07:30AM  Stemline Therapeutics to Present at Upcoming Investor Conferences GlobeNewswire
Jan-30-18 11:02AM  Top 3 Growth Stocks For The Month Simply Wall St.
Jan-26-18 10:21AM  Stemline Therapeutics Closes $59.6 Million Public Offering of Common Stock GlobeNewswire +6.41%
Jan-24-18 07:00AM  Stemline Therapeutics Prices $51.8 Million Public Offering of Common Stock GlobeNewswire +7.77%
Jan-22-18 04:01PM  Stemline Therapeutics Announces Proposed Public Offering of Common Stock GlobeNewswire +5.17%
Jan-09-18 07:30AM  Detailed Research: Economic Perspectives on Fluidigm, Stemline Therapeutics, NeoGenomics, CVR Energy, W.R. Berkley, and Mack-Cali Realty What Drives Growth in Today's Competitive Landscape GlobeNewswire
Jan-08-18 02:24PM  Newman Ferrara LLP Announces Corporate Governance Investigation of Stemline Therapeutics Inc. - STML Business Wire -5.12%
Jan-04-18 08:00AM  Stemline Therapeutics to Present at the 36th Annual J.P. Morgan Healthcare Conference GlobeNewswire -5.00%
Dec-26-17 12:11PM  ETFs with exposure to Stemline Therapeutics, Inc. : December 26, 2017 Capital Cube
Dec-25-17 11:02AM  Best-In-Class Growth Stocks Simply Wall St.
09:26AM  Stemline Therapeutics, Inc. :STML-US: Earnings Analysis: Q3, 2017 By the Numbers : December 25, 2017 Capital Cube
Dec-13-17 08:47AM  Stemline Therapeutics shares jump 4% premarket after positive trial of leukemia treatment MarketWatch
08:36AM  Stemline Therapeutics Presents Detailed SL-401 Pivotal Data in BPDCN at ASH and Kicks Off its BPDCN Awareness Campaign; Updated Results From Ongoing Trials in Additional Malignancies Also Presented GlobeNewswire
Dec-08-17 07:00AM  Stemline Therapeutics Announces Four SL-401 Presentations at Upcoming ASH Meeting GlobeNewswire
Nov-16-17 07:00AM  Stemline Therapeutics Announces Oral Presentation of SL-701 Phase 2 Data in Second-Line Glioblastoma at the 22nd Annual Meeting of the Society of Neuro-Oncology (SNO) GlobeNewswire
Nov-09-17 05:14PM  Stemline Therapeutics reports 3Q loss Associated Press
Stemline Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, acquisition, development, and commercialization of oncology therapeutics in the United States and internationally. The company offers ELZONRIS, a targeted therapy directed to the interleukin-3 receptor (CD123) for patients with blastic plasmacytoid dendritic cell neoplasm in adults, and in pediatric patients two years and older. It also developing CD123 that is in Phase I/II clinical trials for the treatment of chronic myelomonocytic leukemia and myelofibrosis, as well as acute myeloid leukemia and multiple myeloma in combination with other therapies. In addition, the company is developing SL-801, a novel oral small molecule reversible inhibitor of nuclear transport protein, which is in Phase I clinical trial for the treatment of solid and hematologic cancers; and SL-701, an immunotherapy that has completed Phase II clinical trials to treat brain cancer. Its preclinical pipeline products include SL-501, a CD123 targeted therapy; SL- 1001, an oral, selective small molecule RET kinase inhibitor targeting multiple oncology indications; and SL-901, a small molecule kinase inhibitor. Stemline Therapeutics, Inc. was founded in 2003 and is based in New York, New York.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Hoberman KennethChief Operating OfficerMay 14Sale14.2725,817368,409729,879May 17 09:29 PM
Hoberman KennethChief Operating OfficerMar 12Sale11.0498110,830755,696Mar 15 09:00 PM
Gionco DavidChief Accounting OfficerMar 12Sale11.055305,857224,938Mar 15 09:00 PM
Bergstein IvanChief Executive OfficerMar 12Sale11.052,15123,7692,662,127Mar 15 09:01 PM
Bergstein IvanChief Executive OfficerMar 11Sale11.1155,073611,8612,664,278Mar 15 09:01 PM
Gionco DavidChief Accounting OfficerMar 11Sale11.1113,492149,896225,468Mar 15 09:00 PM
Hoberman KennethChief Operating OfficerMar 11Sale11.1125,101278,872756,677Mar 15 09:00 PM
Hoberman KennethChief Operating OfficerMar 07Sale11.362,99534,023781,778Mar 08 09:31 PM
Bergstein IvanChief Executive OfficerMar 07Sale11.416,80077,5882,719,351Mar 08 09:30 PM
Gionco DavidChief Accounting OfficerMar 07Sale11.321,38115,633238,960Mar 08 09:30 PM
Gionco DavidChief Accounting OfficerFeb 25Sale12.038,563103,013240,341Feb 27 09:10 PM
Bergstein IvanChief Executive OfficerFeb 25Sale12.0322,905275,5472,726,151Feb 27 09:09 PM
Hoberman KennethChief Operating OfficerFeb 25Sale12.0510,557127,212784,773Feb 27 09:10 PM
Bergstein IvanChief Executive OfficerFeb 14Sale10.9834,132374,7692,749,056Feb 15 09:31 PM
Hoberman KennethChief Operating OfficerJan 08Sale10.1513,547137,502646,652Jan 11 09:30 PM
Hoberman KennethChief Operating OfficerNov 26Sale11.8526,296311,608659,738Nov 30 08:59 PM